MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cncr.70524

Медицинская библиотека · Cancer · 2026

Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study.

Mustafa Ali Moaath K, Zabor Emily C, Abdurakhmanov Kamilla, Zureigat Hadil, Mohamed Ahmed N, Alchirazi Muaz Alsabbagh, Dhakal Aastha, Mushtaq Ali, Rehman Naveen, Bawwab Ameed, Berube Bryan, Khatib Lana, Jain Akriti G, Molina John C, Balderman Sophia, Singh Abhay, Gerds Aaron T, Sobecks Ronald, Advani Anjali S, Carraway Hetty E, Kalaycio Matt, Mukherjee Sudipto

СтатьяПеревод в очереди

Аннотация

BACKGROUND

No large, randomized trials have compared three or more tyrosine kinase inhibitors (TKIs) in a single chronic myeloid leukemia (CML) cohort. Most studies are two-arm comparisons versus imatinib, or rely on indirect methods.

METHODS

A retrospective cohort study was conducted of 349 patients with chronic- and accelerated-phase CML treated between 2007 and 2023 at Cleveland Clinic centers in Northeast Ohio. Overall survival (OS), event-free survival (EFS), 12-month therapeutic milestone achievement, and BCR-ABL1 transcript decline velocity across first-, second-, and third-line TKIs were compared. Baseline demographics, comorbidities, cytogenetics, and hematologic parameters were collected. Multivariable regression and time-dependent Cox models were adjusted for confounders and varying therapy initiation times.

RESULTS

First-line TKIs included imatinib (53%), dasatinib (30%), nilotinib (15%), and bosutinib (2%). Median age ranged from 52 to 60 years, most patients were White, and high-risk cytogenetics were rare. Five-year OS ranged from 78% for dasatinib to 90% for nilotinib, with nilotinib associated with improved OS (hazard ratio [HR], 0.43) and EFS (HR, 0.48) and the fastest BCR-ABL1 decline (β = -8.3%) versus imatinib. In second- (n = 181) and third-line therapy (n = 91), no significant differences in outcomes were observed. Across all lines, time-dependent modeling showed improved EFS only for nilotinib (HR, 0.61). Unadjusted OS was higher in patients starting treatment in 2007-2010 versus later periods but differences disappeared after adjustment.

CONCLUSIONS

Real-world data indicate that imatinib achieves comparable response rates to newer TKIs, with durable survival. Nilotinib consistently shows faster BCR-ABL1 decline and improved EFS overall, consistent with prior network meta-analyses. Lack of improvement in OS over time suggests the need to investigate factors influencing long-term outcomes in CML.

Для цитирования: Mustafa Ali Moaath K, Zabor Emily C, Abdurakhmanov Kamilla, Zureigat Hadil, Mohamed Ahmed N, Alchirazi Muaz Alsabbagh, Dhakal Aastha, Mushtaq Ali, Rehman Naveen, Bawwab Ameed, Berube Bryan, Khatib Lana, Jain Akriti G, Molina John C, Balderman Sophia, Singh Abhay, Gerds Aaron T, Sobecks Ronald, Advani Anjali S, Carraway Hetty E, Kalaycio Matt, Mukherjee Sudipto. Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study.. Cancer. 2026. DOI: 10.1002/cncr.70524.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.